金域医学(603882.SH)拟定增募资不超10亿元 国投招商管理的基金认购8.5亿元
格隆汇4月15日丨金域医学(603882.SH)披露2020年度非公开发行A股股票预案,拟非公开发行的股票数量合计不超过2073.4万股(含2073.4万股),发行数量不超过此次非公开发行前公司总股本的30%;非公开发行股票的价格为48.23元/股。
募集资金总额不超过10亿元,扣除发行费用后将用于偿还银行贷款和补充流动资金。
发行对象为2名特定对象,包括外部战略投资者国投招商管理的先进制造产业投资基金二期及公司控股股东暨实际控制人梁耀铭。其中,先进制造产业投资基金二期认购8.5亿元,梁耀铭认购1.5亿元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.